This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Free Reports

Biogen to Cut 11% of Workforce, Multiple Sclerosis Drugs Sales Improve

The company raised earnings and revenue guidance modestly for the remainder of the year due to the cost savings from the restructuring.

Relypsa Expects Approval Decision Wednesday on Potassium-Lowering Drug

A positive nod from the FDA will prompt Redwood City, Calif-based Relypsa to finalize the hiring of a salesforce and start selling the drug within the next two months.

Bluebird Shares Plunge on Waning Effect of Old Gene Therapy

All of Bluebird's ongoing clinical trials in beta-thalassemia and sickle cell disease use an improved, more potent gene therapy, the company said.

Zafgen Future Imperiled by New Safety Risk Tied to Obesity Drug

Zafgen is in a tough spot now because the benefit-risk of its lead pipeline drug beloranib is not clear.

Biotech Stock Mailbag: New Sarepta Risk, Zafgen Patient Death, Bluebird Gene Therapy Update

Biotech columnist Adam Feuerstein answers readers' questions about health care.

Zafgen Discloses Patient Death, Cause Unknown, in Obesity Drug Study.

No rational company allows its shareholders to suffer extreme losses because of a "no comment" policy on market speculation.

BioMarin Secures FDA Panel Date for Duchenne Drug but Where is Sarepta? (Update)

The FDA on Wednesday confirms that Nov. 24 is the date for an advisory committee meeting to review BioMarin's Duchenne drug drisapersen.

Zafgen Cancels Meetings, Investors Fear the Worst

The heady days when a biotech company cancelling investor meetings was interpreted as a good thing -- perhaps a sign of a pending takeover -- appear to be over.

Lilly Sinks as Cholesterol-Lowering Pill Trial Shut Down

Eli Lilly is shutting down clinical development of a cholesterol-lowering pill, removing what could have been the company's next multi-billion-dollar product from its research pipeline.

Vertex to Test New Cystic Fibrosis Drugs, Seeking Broader, More Effective Treatments

Advancing the new Vertex drugs into the clinic should also quiet, but not eliminate, investor concerns about competitors closing the gap on the company's market-dominant position in cystic fibrosis treatments.

Page 4 of 347
Top Rated Stocks Top Rated Funds Top Rated ETFs